R-SABE and ABEL versus Blood Volume [Design Issues]

posted by Lucas – Brazil, 2015-08-11 18:06 (3468 d 14:10 ago) – Posting: # 15231
Views: 6,109

Hi to everybody.

RSABE and ABEL came to aid in studies of HVDs/ HVDPs, but what must we do when we are dealing with a fixed dose combination (FDC) that has, for instance, 3 drugs with different PK, and consequently different blood sampling schedule, and one of the drugs is a HVD?

Take Clorpheniramine + Phenylephrine + Paracetamol as a example. We are worried with Phenylephrine's ISCV and want to use the ABEL approach for it, but for the other 2 drugs we don't feel that there is need for that. If I use a replicated design, even a 3-period one, the sampling schedule is very compromised. In Brazil we have a limit of 530mL of blood per study, so no more than that can be withdrawn from the subjects in the entire study.

So my question is: is it possible to not use the replicated samples for the other 2 drugs and apply conventional ABE for them, and consider the replication only for the HVD? Does that make sense? For me this seems a bit bizarre and questionable, in ethics and in GxP. Other option would be to use Balaam's 4x2 design, but I don't think that someone has budget for that... :-D

THX in advance.

Lucas

Complete thread:

UA Flag
Activity
 Admin contact
23,376 posts in 4,912 threads, 1,667 registered users;
148 visitors (0 registered, 148 guests [including 7 identified bots]).
Forum time: 07:17 CET (Europe/Vienna)

The great tragedy of Science – the slaying
of a beautiful hypothesis by an ugly fact.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5